In 1985 a multidisciplinary study on the aetiology of thyroid cancer was set up in Norway. The main target was the high incidence of this type of cancer in fishing communities in northern Norway (Thoresen et al., 1986) , supporting the hypothesis that excess intake of iodide may be a carcinogenic factor for papillary adenocarcinoma of the thyroid gland (Williams et al., 1977) . As another line of investigation, we studied possible pathobiological mechanisms in the thyroid gland before the clinical appearance of tumour at a time when the organ is probably exposed to carcinogenic factors and accordingly under some kind of biological stress.
This study was made possible by matching persons with blood samples in a biological serum bank containing 300,000 sera from 100,000 Norwegians (Janus) with the nationwide Cancer Registry of Norway. By the end of 1985 2,500 persons in the serum bank had developed cancer. Among these were 47 subjects with a malignant tumour. To detect possible biological stress, perturbations in thyroglobulin (S-Tg) and thyroid-stimulating hormone (S-TSH) levels in sera taken several years before clinical appearance of tumour were measured. The serum values in these future cancer patients were compared to those of matched, healthy controls, in which no cancer had occurred by the end of 1985. Accordingly, the design of the investigation was that of a case control study.
Thyroglobulin is a large glycoprotein produced by the follicular cells in the thyroid gland. Due to the widespread use of radioimmunoassay for S-Tg, there have been several reports on the role of S-Tg in the follow-up of patients with thyroid cancer (Girelli et al., 1985) . It has been remarked by several authors that the S-Tg levels are dependent on histological types, medullary and anaplastic having normal or very low values (Pacini et al., 1980) . It has also been claimed that S-Tg is of no value in the initial diagnosis of thyroid cancer, since the test does not discriminate between benign and malignant thyroid conditions (Pacini et al., 1980 (Jellum et al., 1986) . The collection includes sera from cohort studies on cardiovascular disease conducted in 4 different counties in Norway. Up to 3 consecutive samples are available from each person. In addition, specimens from more than 25,000 Red Cross blood donors are continually being added to the collection, and from 2 to 13 (average 4) consecutive samples are available from each donor. The sera are stored at -. 25°C. The earliest specimens date from 1973 and about 100,000 persons had made donations at the time of the present investigation. The Janus collection has been matched with the files in the Cancer Registry. Of a total of 2,500 cancer patients, 47 had malignant thyroid tumours.
For each cancer patient 3 controls were selected from the serum bank matched for sex, age (±3 years), calendar year of blood-sampling and geographical region. Samples from cases and controls were randomly numbered and distributed for assay purposes and the code was not broken until all analytical results were reported.
Histological review was undertaken on all slides, which were classified according to the World Health Organisation (WHO, 1982) . Routine slides stained with haematoxylin and eosin were used. One tumour was judged to be benign and excluded from further studies. In addition we found one cancer of the medullary type (S-Tg=0). As mentioned below 2 cases and 1 control with autoantibodies against S-Tg were also excluded, leaving 43 cases (13 males; 30 females) and 128 corresponding controls for further studies.
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commercial human thyroglobulin immunoradiometric assay kit from Sorin, Saluggia, Italy. The detection limit, based on studies with water banks, was <2pgl-1. S-Tg values in patients after total thyroidectomy were <3 pgl-1. The intraassay coefficient of variation (CV) was 3.9%, and inter-assay CV was 7.2%, within the range 5-lOOgl 1 All sera were tested for thyroglobulin antibodies with a commercial haemagglutination kit, 'Thymune-T' (Wellcome Diagnostics, Dartford, U.K.). Sera containing autoantibodies against thyroglobulin were excluded from the study.
TSH was measured with an ultrasensitive commercial immunoradiometric assay 'Sucrosep TSH IRMA' (Boots Celltech, Berkshire, U.K.) with a typical limit of detection 0.07mUl1-(zero standard+3 s.d.), normal range 0.1-8.0mUl-1 (0-99.7 percentile), and inter-assay CV 6% at the upper normal limit.
Cases and controls were allocated to a 2 x4 contingency table according to level of S-Tg and relative risks for cases versus controls computed. The global test for homogeneity, a x2 test for trend, and 95% confidence intervals for the relative risks (odds ratio) were calculated (Breslow & Day, 1980) .
Results
The essential finding of the study was the difference in S-Tg between cases and controls. In Table I both groups are classified according to increasing S-Tg intervals (both sexes combined). Twelve of 43 (28%) had S-Tg values >lSOpgl-1, compared with only 3 out of 128 (2%) controls. The difference between patients and controls in Table I is statistically significant (P<0.0005) according to the global test. Table I also shows that the odds ratio increases with increasing S-Tg values. Although the figures in some of the windows of the table are small, the conclusion is that the higher odds ratios are significantly > 1 (P <0.05). There is also a statistically significant (P<0.0005) upward trend in the odds ratios with increasing S-Tg level.
The scatter-diagram in Figure 1 illustrates the S-Tg values for all cases both sexes combined. The x-axis gives the time between blood sampling and cancer diagnosis (interval-time). Both high and low S-Tg values are scattered along the x-axis without any distinct pattern, although there is a trend (grouped data) toward higher values nearer tumour presentation.
Of particular interest is the relation of histological type to S-Tg level. Histological review of the material showed that 36 cases had papillary thyroid cancer, while 4 were of the follicular type and 3 tumours were anaplastic. Figure 1 indicates that all the non-papillary types were associated with relatively high S-Tg values, while only 7 of the 36 papillary tumours had this high level. Also of interest is the high level of S-Tg in the 3 patients with anaplastic tumours.
Considering the S-Tg levels alone in the 36 cases with papillary tumour and their corresponding controls, the odds ratios increase with increasing S-Tg levels, and the global test is significant (P<0.005).
Most of the cases were in the age group 40 to 55 years.
Age at diagnosis and age at time of blood sampling had no influence on the level of S-Tg (Table II (Myking & Unjem, 1983) .
It was possible to accomplish this study solely because of the unique Janus blood sample collection and its linkage to the nationwide Cancer Registry of Norway. All slides have been reviewed. The laboratory tests used are well established and in clinical use as routine tests in patients with different types of thyroid diseases (Black et al., 1981) .
The essential finding of the present investigation is the difference in S-Tg in blood samples between cases and controls, which is highly significant.
To our knowledge, no reports have been published on the level of S-Tg in the preclinical phase of thyroid cancer. At diagnosis, but before therapy, other investigations have reported that 43% (16/37) of patients with papillary carcinomas and 81% (21/26) of patients with follicular carcinomas have S-Tg elevation above the 97.5 percentile (40,ugl-1) of the normal range (Refetoft & Lever, 1983) . There is general agreement that patients with anaplastic carcinomas usually do not have S-Tg elevation (Pacini et al., 1980; Black et al., 1981; Ericsson et al., 1984; Torriginai et al., 1969; Basclueri et al., 1981) , but such elevation can occur (Feldt-Rasmussen et al., 1983; Bottger et al., 1980; Monaco et al., 1983) . We found that 25% (9/36) of cases with papillary, 100% (4/4) with follicular and 100% (3/3) with anaplastic carcinomas had S-Tg >90 jug l-years before cancer diagnosis. This shows that in papillary and follicular carcinomas there is no fundamental change in S-Tg levels from the preclinical to the clinical stage developing years later.
With regard to the prolonged preclinical elevation of S-Tg, this should be evaluated in conjunction with the lack of difference in S-TSH between cases and controls. Whatever the explanation for the elevated S-Tg in our cases, it is clear that the gland has not been stressed or hyperactivated by TSH during the period prior to diagnosis. Moreover, the prolonged latency period from S-Tg elevation to clinical tumour manifestation suggests a continued release from dormant tumour cells rather than from destruction of adjacent thyroid follicles being actively invaded by growing tumour tissue. Altered histological architecture in a tumour may be responsible for abnormal thyroglobulin release into extracellular fluid and lymphatics, instead of the normal storage in follicles. Autopsy studies have revealed that socalled occult thyroid cancer is present in a high percentage of subjects dying from other unrelated diseases (Refetoft & Lever, 1983) .
Of the three controls (all females) who had S-Tg levels above 150 pg l-1, one was ultimately found to have undergone surgery for simple goitre in 1956, another was to be operated on for the same disease in the near future, and the third was without any symptoms related to the thyroid gland. Strictly speaking, the two women with non-malignant thyroid disease should not have been included as controls, an omission which would have made the difference between cases and controls even more striking. On the other hand, none of the other controls were examined for benign thyroid diseases.
We conclude that S-Tg tends to be increased years before the clinical appearance of thyroid carcinoma, whereas S-TSH is not elevated. This implies that the initiating carcinogenic factors do not act even partially, by inhibition of thyroid hormone production, with secondary TSH stimulation leading to tumour promotion and progression. Whether the increased S-Tg is a secretory product from slowly growing subclinical tumours or a leakage phenomenon from normal follicles cannot be answered by our data. The frequency of elevated S-Tg seems to be of the same magnitude in the preclinical as in the early clinical stage of thyroid carcinoma. Despite this, S-Tg determination has poor predictive value as a screening test for thyroid malignancy, because of its low specificity and the low prevalence of the disease. Unexplained increased S-Tg values, however, should indicate close follow-up of the patient.
